Zions Bancorporation N.A. Has $101,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Zions Bancorporation N.A. trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 27.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 216 shares of the pharmaceutical company’s stock after selling 83 shares during the quarter. Zions Bancorporation N.A.’s holdings in Vertex Pharmaceuticals were worth $101,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. University of Texas Texas AM Investment Managment Co. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $25,000. Annapolis Financial Services LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $27,000. ICA Group Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth about $28,000. GHP Investment Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Stephens Consulting LLC bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $31,000. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $471.72, for a total value of $1,075,521.60. Following the completion of the transaction, the chief marketing officer now directly owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total value of $1,075,521.60. Following the completion of the sale, the chief marketing officer now directly owns 30,099 shares of the company’s stock, valued at approximately $14,198,300.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Reshma Kewalramani sold 15,202 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $497.00, for a total value of $7,555,394.00. Following the transaction, the chief executive officer now directly owns 106,172 shares in the company, valued at approximately $52,767,484. The disclosure for this sale can be found here. Insiders have sold a total of 34,047 shares of company stock worth $16,843,806 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent analyst reports. TD Cowen lifted their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Canaccord Genuity Group upped their target price on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a research note on Wednesday, July 31st. Truist Financial restated a “buy” rating and issued a $550.00 price target (up from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Redburn Atlantic assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, June 27th. They set a “buy” rating and a $545.00 price objective for the company. Finally, Guggenheim lifted their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $485.91.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $485.37 on Monday. The stock has a market capitalization of $125.25 billion, a P/E ratio of 31.50 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.85 and a 1 year high of $510.64. The firm has a 50 day moving average of $483.72 and a 200-day moving average of $450.41. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the firm posted $3.53 EPS. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.